FY2024 Earnings Estimate for GYRE Issued By Noble Financial

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Noble Financial issued their FY2024 earnings per share (EPS) estimates for shares of Gyre Therapeutics in a report issued on Tuesday, March 11th. Noble Financial analyst R. Leboyer expects that the company will post earnings per share of $0.17 for the year. Noble Financial has a “Outperform” rating on the stock. Noble Financial also issued estimates for Gyre Therapeutics’ Q4 2024 earnings at $0.04 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.17 EPS, FY2027 earnings at $1.72 EPS and FY2028 earnings at $2.90 EPS.

Gyre Therapeutics Trading Up 2.8 %

Shares of GYRE opened at $11.67 on Thursday. The business’s fifty day simple moving average is $11.24 and its two-hundred day simple moving average is $12.32. Gyre Therapeutics has a 12 month low of $8.26 and a 12 month high of $19.96.

Insider Transactions at Gyre Therapeutics

In other news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now directly owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 34,054 shares of company stock worth $383,057 in the last ninety days. Insiders own 19.52% of the company’s stock.

Hedge Funds Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC purchased a new position in shares of Gyre Therapeutics in the 3rd quarter worth $47,000. Wells Fargo & Company MN boosted its stake in shares of Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after buying an additional 913 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after buying an additional 1,996 shares during the last quarter. Barclays PLC boosted its stake in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Gyre Therapeutics by 11.1% in the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after buying an additional 1,389 shares during the last quarter. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.